| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B B Yao, S Mukherjee, Y Fan, T R Garrison, A V Daza, G K Grayson, B A Hooker, M J Dart, J P Sullivan, M D Meye. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? British journal of pharmacology. vol 149. issue 2. 2007-01-09. PMID:16894349. |
in vitro pharmacological characterization of am1241: a protean agonist at the cannabinoid cb2 receptor? |
2007-01-09 |
2023-08-12 |
Not clear |
| Cristina Blázquez, Arkaitz Carracedo, Lucía Barrado, Pedro José Real, José Luis Fernández-Luna, Guillermo Velasco, Marcos Malumbres, Manuel Guzmá. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 20. issue 14. 2007-01-01. PMID:17065222. |
human melanomas and melanoma cell lines express cb1 and cb2 cannabinoid receptors. |
2007-01-01 |
2023-08-12 |
mouse |
| Angelo Jayamanne, Ruth Greenwood, Vanessa A Mitchell, Sevda Aslan, Daniele Piomelli, Christopher W Vaugha. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. British journal of pharmacology. vol 147. issue 3. 2006-12-26. PMID:16331291. |
the effects of urb597 in the cfa model were dose dependent and were reduced by coadministration with the cannabinoid cb1 antagonist am251 (1 mg kg(-1)), or the cb2 and sr144528 (1 mg kg(-1)). |
2006-12-26 |
2023-08-12 |
rat |
| Angelo Jayamanne, Ruth Greenwood, Vanessa A Mitchell, Sevda Aslan, Daniele Piomelli, Christopher W Vaugha. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. British journal of pharmacology. vol 147. issue 3. 2006-12-26. PMID:16331291. |
these findings suggest that the faah inhibitor urb597 produces cannabinoid cb1 and cb2 receptor-mediated analgesia in inflammatory pain states, without causing the undesirable side effects associated with cannabinoid receptor activation. |
2006-12-26 |
2023-08-12 |
rat |
| Paola Nieri, Nadia Romiti, Barbara Adinolfi, Andrea Chicca, Ilaria Massarelli, Elisabetta Chiel. Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. British journal of pharmacology. vol 148. issue 5. 2006-12-26. PMID:16715117. |
rt-pcr demonstrated that hk-2 cells do not express cb1 or cb2 cannabinoid receptors. |
2006-12-26 |
2023-08-12 |
Not clear |
| Régis Roche, Laurence Hoareau, Sandrine Bes-Houtmann, Marie-Paule Gonthier, Christine Laborde, Jean-François Baron, Yacine Haffaf, Maya Cesari, Franck Fest. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochemistry and cell biology. vol 126. issue 2. 2006-12-15. PMID:16395612. |
presence of the cannabinoid receptors, cb1 and cb2, in human omental and subcutaneous adipocytes. |
2006-12-15 |
2023-08-12 |
human |
| Xundi Xu, Yi Liu, Shengfu Huang, Guoxing Liu, Chengzhi Xie, Jun Zhou, Wentao Fan, Qinglong Li, Qunwei Wang, Dewu Zhong, Xiongying Mia. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer genetics and cytogenetics. vol 171. issue 1. 2006-12-15. PMID:17074588. |
overexpression of cannabinoid receptors cb1 and cb2 correlates with improved prognosis of patients with hepatocellular carcinoma. |
2006-12-15 |
2023-08-12 |
human |
| Xundi Xu, Yi Liu, Shengfu Huang, Guoxing Liu, Chengzhi Xie, Jun Zhou, Wentao Fan, Qinglong Li, Qunwei Wang, Dewu Zhong, Xiongying Mia. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer genetics and cytogenetics. vol 171. issue 1. 2006-12-15. PMID:17074588. |
our results indicate that cb1 and cb2 have potential as prognostic indicators and suggest possible beneficial effects of cannabinoids on prognosis of patients with hcc. |
2006-12-15 |
2023-08-12 |
human |
| Kathline Kim, Dan H Moore, Alexandros Makriyannis, Mary E Aboo. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. European journal of pharmacology. vol 542. issue 1-3. 2006-12-14. PMID:16781706. |
am1241, a cannabinoid cb2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. |
2006-12-14 |
2023-08-12 |
mouse |
| Kathline Kim, Dan H Moore, Alexandros Makriyannis, Mary E Aboo. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. European journal of pharmacology. vol 542. issue 1-3. 2006-12-14. PMID:16781706. |
am1241 is a cannabinoid cb2 receptor selective agonist that has been shown to be effective in models of inflammation and hyperalgesia. |
2006-12-14 |
2023-08-12 |
mouse |
| Kathline Kim, Dan H Moore, Alexandros Makriyannis, Mary E Aboo. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. European journal of pharmacology. vol 542. issue 1-3. 2006-12-14. PMID:16781706. |
as am1241 was well tolerated by the animals, cannabinoid cb2 receptor-selective compounds may be the basis for developing new drugs for the treatment of als and other chronic neurodegenerative diseases. |
2006-12-14 |
2023-08-12 |
mouse |
| Tatsuya Maekawa, Hiroshi Nojima, Yasushi Kuraishi, Kazuo Aisak. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. European journal of pharmacology. vol 542. issue 1-3. 2006-12-14. PMID:16824511. |
the cannabinoid cb2 receptor inverse agonist jte-907 suppresses spontaneous itch-associated responses of nc mice, a model of atopic dermatitis. |
2006-12-14 |
2023-08-12 |
mouse |
| Tatsuya Maekawa, Hiroshi Nojima, Yasushi Kuraishi, Kazuo Aisak. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. European journal of pharmacology. vol 542. issue 1-3. 2006-12-14. PMID:16824511. |
jte-907, n-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide, is a selective cannabinoid cb2 receptor antagonist/inverse agonist. |
2006-12-14 |
2023-08-12 |
mouse |
| Magdalena Zaniewska, Andrew C McCreary, Edmund Przegaliński, Małgorzata Fili. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. European journal of pharmacology. vol 540. issue 1-3. 2006-12-11. PMID:16730696. |
during test sessions the following drugs were coadministered with saline (substitution studies) or nicotine (0.025-0.4 mg/kg; combination studies): the alpha4beta2 nicotinic acetylcholine receptor subtype antagonist dihydro-beta-erythroidine (dhbetae), the non-selective nicotinic acetylcholine receptor subtype antagonist mecamylamine, the alpha7 nicotinic acetylcholine receptor subtype antagonist methyllycaconitine (mla), the alpha4beta2 nicotinic acetylcholine receptor subtype agonist 5-iodo-3-(2(s)-azetidinylmethoxy)pyridine (5-ia), the cannabinoid cb1 receptor antagonist/partial agonist rimonabant, the cannabinoid cb2 receptor antagonist n-[(1s)-endo-1,3,3-trimethylbicyclo-[2.2.1]heptan-2-yl]5-(4-chloro-3-methyl-phenyl)-1-(4-methybenzyl)pyrazole-3-carboxamide (sr 144528), the cannabinoid cb1/2 receptor agonists (-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)-phenyl]-trans-4-(3-hydroxy-propyl)cyclohexanol (cp 55,940) or r(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]-pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-(1-naphthalenyl)-methanone mesylate (win 55,212-2), the endogenous cannabinoid agonist and non-competitive alpha7 nicotinic acetylcholine receptor subtype antagonist anandamide, the anandamide uptake and fatty acid amide hydrolase inhibitor n-(4-hydroxyphenyl)-5z,8z,11z,14z-eicosatetraenamide (am-404), the fatty acid amide hydrolase inhibitor cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester (urb 597), am-404+anandamide or urb 597+anandamide. |
2006-12-11 |
2023-08-12 |
rat |
| Magdalena Zaniewska, Andrew C McCreary, Edmund Przegaliński, Małgorzata Fili. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. European journal of pharmacology. vol 540. issue 1-3. 2006-12-11. PMID:16730696. |
furthermore, we excluded the involvement of either cannabinoid cb1 and cb2 receptors or increases in the endocannabinoid tone in the nicotine discrimination. |
2006-12-11 |
2023-08-12 |
rat |
| John W Huffman, Lea W Padgett, Matthew L Isherwood, Jenny L Wiley, Billy R Marti. 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorganic & medicinal chemistry letters. vol 16. issue 20. 2006-12-04. PMID:16889960. |
1-alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid cb1 and cb2 receptors. |
2006-12-04 |
2023-08-12 |
Not clear |
| M G Cascio, T Bisogno, E Palazzo, A Thomas, M van der Stelt, A Brizzi, V de Novellis, I Marabese, R Ross, T van de Doelen, V Brizzi, R Pertwee, S Maione, V Di Marz. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands. British journal of pharmacology. vol 149. issue 4. 2006-11-28. PMID:16953186. |
we have previously reported the development of cb-25 and cb-52, two ligands of cb1 and cb2 cannabinoid receptors. |
2006-11-28 |
2023-08-12 |
Not clear |
| Javier Palazuelos, Tania Aguado, Ainara Egia, Raphael Mechoulam, Manuel Guzmán, Ismael Galve-Roper. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 20. issue 13. 2006-11-27. PMID:17015409. |
non-psychoactive cb2 cannabinoid agonists stimulate neural progenitor proliferation. |
2006-11-27 |
2023-08-12 |
mouse |
| Charles A Lunn, Eva-Pia Reich, Loretta Bobe. Targeting the CB2 receptor for immune modulation. Expert opinion on therapeutic targets. vol 10. issue 5. 2006-11-14. PMID:16981823. |
in this report, the authors investigate the role of the cannabinoid cb2 receptor in immune regulation, with particular emphasis on compounds shown to regulate immune cell recruitment. |
2006-11-14 |
2023-08-12 |
Not clear |
| Charles A Lunn, Eva-Pia Reich, Loretta Bobe. Targeting the CB2 receptor for immune modulation. Expert opinion on therapeutic targets. vol 10. issue 5. 2006-11-14. PMID:16981823. |
the authors conclude by using the immune cell recruitment model to rationalise cannabinoid cb2 receptor-specific effects in modulating immune disease, particularly the increasing evidence for its role in experimental autoimmune encephalomyelitis and in influencing bone density. |
2006-11-14 |
2023-08-12 |
Not clear |